Treatment
CD19 CAR-T cells clinical trials
We’re tracking 195 recruiting studies that include CD19 CAR-T cells, each written for real people, not researchers, below.
Recruiting studies
- NCT07233642RecruitingPhase 1
Fast CD19 CAR-T therapy for lupus not helped by standard treatment
This trial tests a quick-made CAR-T cell therapy for children and adults with active lupus who haven't gotten better with standard drugs. The goal is to see if targeting a protein called CD19 on certain immune cells can calm the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT07681388Recruiting
CAR-T cell therapy for hard-to-treat pemphigus
This study tests a new type of immune therapy called CAR-T cells, made from your own blood cells, to treat severe pemphigus vulgaris that hasn't responded to standard treatments like steroids and rituximab. The goal is to see if this treatment can control the disease and reduce the need for ongoing medications.
Wuhan, HubeiAges 18–70 - NCT07261345RecruitingEarly Phase 1
CAR-T cell therapy for hard-to-treat Graves' disease
This early-phase trial tests whether specially engineered immune cells (called CAR-T) can treat Graves' disease that hasn't responded to standard medication. It's for people with active, hard-to-control Graves' who have the TRAb antibody.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07266181RecruitingPhase 1
CAR-T cell therapy for tough-to-treat membranous nephropathy
This trial tests whether specially engineered immune cells (CAR-T cells) can help people with a kidney condition called primary membranous nephropathy that has not improved with standard treatments. The goal is to see if this therapy can reduce protein in the urine and protect kidney function.
Xi'an, ChinaAges 18 years+ - NCT07331467RecruitingPhase 1
Ultra-fast CAR-T cell therapy for lupus
This trial tests a new CAR-T cell treatment for people with lupus who still have moderate to severe symptoms despite trying standard medications. It aims to quickly stop the immune system from attacking the body.
Nanjing, JiangsuAges 18 years+ - NCT07339332RecruitingEarly Phase 1
CAR-T cell therapy for moderate to severe lupus
This study tests whether a new CAR-T cell treatment (called CT1195E) can help people with lupus that hasn't improved with standard medicines. CAR-T cells are specially trained immune cells that seek out and destroy certain faulty immune cells, which may reduce lupus symptoms. The trial is for people with moderate to severe active lupus affecting organs like the kidneys, heart, or blood system.
Wuhan, HubeiAges 18–65 - NCT07478848RecruitingPhase 1
Radiation, Vancomycin, and CAR-T for B-cell lymphoma
This trial tests whether giving radiation and an oral antibiotic (vancomycin) before CAR-T therapy helps treat B-cell lymphoma more effectively. It is for people who are already scheduled to receive CAR-T treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07361029RecruitingPhase 1
CAR T cell therapy for adults with returning B-cell leukemia
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
Riyadh, Riyadh RegionAges 18–75 - NCT07368270RecruitingPhase 1
Anti-PD1 armored CAR-T cells for adults with relapsed/refractory DLBCL
This trial tests a new kind of cell therapy that combines CAR-T cells (which find and kill cancer cells) with an anti-PD1 'armor' to boost their power. It is for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to earlier treatments.
SuzhouAges 18 years+ - NCT07369492RecruitingPhase 1
Study of BAFF-R CAR-T cells for CD19-negative B-cell lymphoma
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
SuzhouAges 18 years+ - NCT07398963RecruitingPhase 1
Virus-based CAR-T therapy for relapsed B-cell lymphoma
This trial uses a modified virus to deliver CAR-T cells directly into tumors, aiming to treat B-cell lymphoma that has come back or not responded to other treatments. It may be an option if your lymphoma is CD19-positive and you've tried at least two prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT07441291RecruitingPhase 3
CAR-T vs donor immune cells for residual leukemia after transplant
This study tests whether a therapy using your own immune cells (CAR-T) works better than donor immune cells (DLI) to remove leftover leukemia cells after a stem cell transplant. The goal is to prevent the leukemia from coming back.
Beijing, ChinaAges 3–79 - NCT07489989RecruitingPhase 2
Combination therapy to boost CAR-T for B-cell lymphoma
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
Beijing, Beijing MunicipalityAges 18–85 - NCT07523542RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Treatment-Resistant Lupus
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
Shenzhen, GuangdongAges 18–70 - NCT07558850Recruiting
CAR-T Cell Therapy for Treatment-Resistant Autoimmune Diseases
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
Nanjing, JiangsuAges 18–70 - NCT07564453RecruitingPhase 2
Immunotherapy plus chemotherapy for newly diagnosed B-cell leukemia
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
Suzhou, JiangsuAges 15–65 - NCT07575919RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Standard-Risk B-ALL After Chemotherapy
This trial tests a new type of immunotherapy called CAR-T cells to help prevent relapse in adults with B-cell acute lymphoblastic leukemia (a blood cancer) who have responded well to standard chemotherapy. The treatment is designed as a consolidation therapy to strengthen remission after initial chemotherapy.
Beijing, Beijing MunicipalityAges 18–85 - NCT07575971RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for High-Risk B-Cell Acute Lymphoblastic Leukemia
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
Beijing, Beijing MunicipalityAges 18–85 - NCT07584889RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Relapsed Blood Cancers
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT07587840RecruitingPhase 2
CAR-T Cell Therapy After Initial Treatment for Follicular Lymphoma
This study tests a new type of immunotherapy called CAR-T cells (designed cells that fight lymphoma) given after you've received standard chemotherapy for follicular lymphoma. The goal is to help prevent the cancer from coming back or growing, especially if your cancer didn't fully disappear or you have high-risk features.
Beijing, Beijing MunicipalityAges 18–85 - NCT06827782Enrolling by invitationPhase 1
Cord blood CAR-NK cells for relapsed CNS lymphoma
This trial tests a new treatment using specially engineered immune cells from cord blood to target and kill cancer cells in the brain or spine. It is for people whose central nervous system lymphoma has not responded to or has returned after previous treatments.
Hangzhou, ZhejiangAges 18–75 - NCT05432882RecruitingPhase 1/Phase 2
CD19/22 CAR-T for certain B-cell blood cancers
This trial tests a lab-made immune treatment (CAR-T cells) designed to attack cancer cells that carry CD19 or CD22. It may help people whose B-cell cancers have those markers, provided they meet safety and health requirements.
Shenzhen, GuangdongAges 6 months–75 years - NCT05436496RecruitingPhase 1/Phase 2
CAR-T treatment for certain CD19 or CD70 blood cancers
This early-phase trial tests a customized immune cell therapy (CAR-T) that targets cancer cells with CD19 or CD70 markers on their surface. It may help your body fight the cancer by directing new immune cells to recognize and attack those cells.
Shenzhen, GuangdongAges 6 months–75 years
Common questions
- Are there clinical trials studying CD19 CAR-T cells?
- Yes. Clin2 currently lists 195 recruiting studies that include CD19 CAR-T cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a CD19 CAR-T cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is CD19 CAR-T cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether CD19 CAR-T cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.